717 related articles for article (PubMed ID: 17686672)
1. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
Horváth G; Tolvaj G; Halász T; Stotz G
Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
[TBL] [Abstract][Full Text] [Related]
2. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
3. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
Pár A; Tornai I; Szalay F
Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
[TBL] [Abstract][Full Text] [Related]
4. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
Yenice N; Mehtap O; Gümrah M; Arican N
Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
[TBL] [Abstract][Full Text] [Related]
7. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
9. Comparative therapeutic response to pegylated interferon plus ribavirin versus interferon alpha-2b in chronic hepatitis C patients.
Ali S; Nazir G; Khan SA; Iram S; Fatima F
J Ayub Med Coll Abbottabad; 2010; 22(4):127-30. PubMed ID: 22455279
[TBL] [Abstract][Full Text] [Related]
10. [Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C].
Pár A
Orv Hetil; 2002 Dec; 143(48):2667-74. PubMed ID: 12501575
[TBL] [Abstract][Full Text] [Related]
11. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
Halász T; Farkas A; Tolvaj G; Horváth G
Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
[TBL] [Abstract][Full Text] [Related]
12. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
13. [Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
Makara M; Horváth G; Gervain J; Pár A; Szalay F; Telegdy L; Tornai I; Ujhelyi E; Hunyady B
Orv Hetil; 2012 Mar; 153(10):375-94. PubMed ID: 22370225
[TBL] [Abstract][Full Text] [Related]
14. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
[TBL] [Abstract][Full Text] [Related]
15. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
16. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic hepatitis C in southern Taiwan.
Chuang WL; Yu ML; Dai CY; Chang WY
Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
19. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.
Baker RD; Dee D; Baker SS
J Clin Gastroenterol; 2007 Jan; 41(1):111-4. PubMed ID: 17198073
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]